Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
Sohal DP, Metz JM, Sun W, Giantonio BJ, Plastaras JP, Ginsberg G, Kochman ML, Teitelbaum UR, Harlacker K, Heitjan DF, Feldman MD, Drebin JA, O'Dwyer PJ. Sohal DP, et al. Among authors: plastaras jp. Cancer Chemother Pharmacol. 2013 Jun;71(6):1485-91. doi: 10.1007/s00280-013-2147-4. Epub 2013 Mar 27. Cancer Chemother Pharmacol. 2013. PMID: 23532207 Clinical Trial.
ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.
Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS; Expert Panel on Radiation OncologyLymphoma. Roberts KB, et al. Among authors: plastaras jp. Am J Clin Oncol. 2016 Aug;39(4):384-95. doi: 10.1097/COC.0000000000000294. Am J Clin Oncol. 2016. PMID: 27299425 Review.
ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.
Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS; Expert Panel on Radiation Oncology–Lymphoma. Dhakal S, et al. Among authors: plastaras jp. Am J Clin Oncol. 2016 Dec;39(6):535-544. doi: 10.1097/COC.0000000000000331. Am J Clin Oncol. 2016. PMID: 27643717 Free PMC article. Review.
Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma.
Boimel PJ, Berman AT, Li J, Apisarnthanarax S, Both S, Lelionis K, Larson GL, Teitelbaum U, Lukens JN, Ben-Josef E, Metz JM, Plastaras JP. Boimel PJ, et al. Among authors: plastaras jp. J Gastrointest Oncol. 2017 Aug;8(4):665-674. doi: 10.21037/jgo.2017.03.04. J Gastrointest Oncol. 2017. PMID: 28890817 Free PMC article.
A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer.
Shabason JE, Chen J, Apisarnthanarax S, Damjanov N, Giantonio B, Loaiza-Bonilla A, O'Dwyer PJ, O'Hara M, Reiss KA, Teitelbaum U, Wissel P, Drebin JA, Vollmer C, Kochman M, Mick R, Vergara N, Jhala N, Doucette A, Lukens JN, Plastaras JP, Metz JM, Ben-Josef E. Shabason JE, et al. Among authors: plastaras jp. Cancer Chemother Pharmacol. 2018 Mar;81(3):609-614. doi: 10.1007/s00280-018-3519-6. Epub 2018 Jan 23. Cancer Chemother Pharmacol. 2018. PMID: 29362902 Clinical Trial.
158 results